Alan H. Bryce, MD

City of Hope

Phoenix, Arizona

Alan H. Bryce, MD, is a medical oncologist and chief clinical officer at City of Hope in Phoenix, Arizona. Dr. Bryce holds an appointment as a professor with the Department of Medical Oncology & Therapeutics Research, with City of Hope, as well as an appointment as a professor of Molecular Medicine at Translational Genomics Research Institute (TGen), which is also part of City of Hope.

Prior to joining City of Hope, Dr. Bryce spent 12 years at the Mayo Clinic in Phoenix, where he served as chair of the Division of Hematology and Medical Oncology, as well as Director of the Mayo Clinic Arizona Comprehensive Cancer Center. Dr. Bryce received his medical degree from the Chicago Medical School, and then completed an internal medicine residency and a hematology and oncology fellowship at the Mayo Clinic in Rochester, Minnesota. During his time at Mayo, Dr. Bryce served as an international co-principal investigator on multiple clinical trials for prostate cancer, with his research focused on cancer genetics, novel therapies and immunotherapeutic approaches.

Talks by Alan H. Bryce, MD

Therapeutic Use of Genetic Testing in Advanced Prostate Cancer

Posted by Alan H. Bryce, MD | Jan 2018

Alan H. Bryce, MD, argues that the urologic community should expand genetic testing in prostate cancer patients. With expansive, quality data, urologists will be able to better recognize aberrations in patients’ genes. Also, this would be a step closer to gaining FDA approved biomarkers for prostate cancer.

Adjuvant Sunitinib for High Risk Renal Cell Carcinoma: Not Ready for Prime Time

Posted by Alan H. Bryce, MD | Jan 2018

Dr. Alan H. Bryce, MD, argues that there is not yet enough substantive data and research to justify the FDA approving using adjuvant Sunitinib to treat high risk renal cell carcinoma.

Germline and Somatic DNA Repair Defects in Prostate Cancer

Posted by Alan H. Bryce, MD | Jan 2018

Dr. Alan H. Bryce, MD, discusses synthetic lethality regarding BRCA deficient tumors, the role of PARP inhibitors and resistance to them, and the importance of germline testing when treating cancer patients.

Immunotherapeutic Agents in Metastatic Bladder Cancer

Posted by Alan H. Bryce, MD | Jan 2018

Dr. Alan H. Bryce, MD, discusses the use of immunotherapy for metastatic disease treatment, the proven survival benefit of certain immunotherapeutic drugs, and summarizes recent advances in immunotherapy as a whole.

The DECIPHER Marker Can Predict Chemotherapy

Posted by Alan H. Bryce, MD | Jan 2018

Alan H. Bryce, MD makes the pro side of the argument that the DECIPHER marker is an effective tool for predicting a patient’s response to chemotherapy. He also summarizes the ongoing trials and research regarding this specific biomarker. This is a counter argument to Robert Abouassaly’s lecture, “Can The DECIPHER Marker Can Predict Chemotherapy?”